Vertex Pharmaceuticals Incorporated (VRTX) financial statements and ratios from SEC XBRL: revenue $12.00B (TTM), net margin 32.9%, revenue growth 12.5% YoY, P/E 31.1. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $12.00B |
| Net Margin | 32.9% |
| Revenue Growth (YoY) | 12.5% |
| EPS Growth (YoY) | 8.0% |
| FCF Growth (YoY) | 9.3% |
| P/E Ratio | 31.1 |
| EV / EBITDA | 26.2 |
| Price / Book | 6.77 |
| Price / Sales | 10.89 |
| FCF Yield | 2.8% |
| DCF Value (model) | $62.94 |
| DCF Upside vs Price | -88.3% |
| Altman Z-Score | 13.89 (safe) |
| Sector P/E (Healthcare) | 21.6 |
VRTX overview · VRTX earnings · VRTX KPIs · VRTX investor relations · VRTX ownership · VRTX peers · VRTX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.